Editorial
Copyright ©The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Meta-Anal. Aug 31, 2019; 7(8): 373-379
Published online Aug 31, 2019. doi: 10.13105/wjma.v7.i8.373
Tofacitinib for the treatment of ulcerative colitis: A review of the literature
Jessica Rosenberg, Joshua M Steinberg, Mark C Mattar
Jessica Rosenberg, Department of Internal Medicine, MedStar Georgetown University Hospital, Washington, DC 20007, United States
Joshua M Steinberg, Mark C Mattar, Department of Gastroenterology, MedStar Georgetown University Hospital, Washington, DC 20007, United States
Author contributions: Rosenberg J, Steinberg JM and Mattar MC conceived the study and drafted the manuscript; all authors approved the final version of the article.
Conflict-of-interest statement: The corresponding author has the following conflicts to disclose: Dr. Mattar reports personal fees from Pfizer, from null, during the conduct of the study; personal fees from Abbvie, from Janssen, outside the submitted work.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Mark C Mattar, MD, FACG, Academic Research, Associate Professor, Department of Gastroenterology, MedStar Georgetown University Hospital, 3800 Reservoir Road NW, Washington, DC 20007, United States. mark.c.mattar@gunet.georgetown.edu
Telephone: +1-202-4448541 Fax: +1-877-3031462
Received: June 18, 2019
Peer-review started: June 21, 2019
First decision: July 21, 2019
Revised: August 15, 2019
Accepted: August 20, 2019
Article in press: August 20, 2019
Published online: August 31, 2019
Processing time: 85 Days and 13.6 Hours
Abstract

Ulcerative colitis (UC) is a chronic immune-mediated inflammatory condition affecting the colon. Recently, tofacitinib, an oral small molecule that is an inhibitor of the Janus kinase signal transduction pathway, was proven efficacious for inducing and maintaining remission in adult patients with moderate to severe UC in three global Phase III studies. The purpose of this review is to summarize existing data on the efficacy, safety, and quality of life issues related to use tofacitinib as well as highlight recent real-world experience with this drug among patients with UC.

Keywords: Ulcerative colitis, Tofacitinib, Review, Inflammatory bowel disease, Treatment

Core tip: Tofacitinib is a small molecule that is an inhibitor of the Janus kinase signal transduction pathway, and it is the first oral medication approved for chronic use among adults with moderately to severely active ulcerative colitis (UC). Three large phase III trials have shown overall efficacy and safety; however, long-term results and real-world data are lacking in the literature. Our objective is it consolidate the current literature to better understand what is currently known about efficacy, safety, quality of life, and real-world experience with this medication among patients with UC.